Chipscreen Biosciences Out-Licenses Taiwanese Rights for Cancer Drug to GNT Biotech and Medicals Corporation

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

October 11, 2013 -- Shenzhen Chipscreen Biosciences has out-licensed Taiwanese rights for a cancer drug candidate, Chidamide, to GNT Biotech and Medicals of Taiwan. Chidamide is an oral, selective histone deacetylase (HDAC) inhibitor that is currently being tested in a China Phase II clinical trial. Financial details of the agreement were not disclosed. More details....

Help employers find you! Check out all the jobs and post your resume.

Back to news